Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

ProMetic Receives $5.1 Million Purchase Order from Multinational Client

Marketwired November 19, 2013

ProMetic Reports its Third Quarter 2013 Highlights and Financial Results

Marketwired November 14, 2013

ProMetic's PBI-4050 Shown to Reduce Heart Fibrosis

Marketwired November 12, 2013

ProMetic to Report its Third Quarter 2013 Highlights and Financial Results and Hold Conference Call/Webcast

Marketwired November 11, 2013

ProMetic Announces the Closing of its Common Share Offering

Marketwired November 7, 2013

ProMetic Achieves Hematech Milestone

Marketwired November 6, 2013

ProMetic Achieves Hematech Milestone

Marketwired November 6, 2013

ProMetic Presents Positive Results for PBI-4050 in Liver Fibrosis

Marketwired November 4, 2013

ProMetic Files Final Prospectus for its Common Share Offering

Marketwired November 1, 2013

ProMetic Announces Terms of Common Share Offering

Marketwired October 22, 2013

ProMetic Files Preliminary Prospectus for an Equity Offering

Marketwired October 21, 2013

ProMetic's Lead Drug Candidate, PBI-4050, Enters Clinical Program

Marketwired September 26, 2013

ProMetic Secures $10.0 Million Loan From Thomvest Seed Capital Inc.

Marketwired September 11, 2013

ProMetic Provides a Novel Potential Treatment for Idiopathic Pulmonary Fibrosis ("IPF") With PBI-4050

Marketwired September 9, 2013

ProMetic Reports Its Second Quarter 2013 Highlights and Financial Results

Marketwired August 14, 2013

ProMetic to Develop and Commercialize Alpha1-Antitrypsin as Second Plasma-Derived Orphan Drug Product

Marketwired August 14, 2013

ProMetic's Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

Marketwired July 11, 2013

ProMetic's Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

Marketwired July 11, 2013

ProMetic Progresses Into a Licensing and Long-Term Supply Agreement With an Existing Multinational Client

Marketwired July 8, 2013

ProMetic Progresses Into a Licensing and Long-Term Supply Agreement With an Existing Multinational Client

Marketwired July 8, 2013